BSE: 531146 | NSE: MEDICAMEQ | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Medicamen Biotech Ltd is a below average quality company.
The key valuation ratios of Medicamen Biotech Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Medicamen Biotech Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 11.6% | 11.4% | 24.1% | 24.9% | 20.2% | 15.3% | 13.1% | 12.8% | 11% | 10.1% | - |
| Value Creation Index ⓘ | -0.2 | -0.2 | 0.7 | 0.8 | 0.4 | 0.1 | -0.1 | -0.1 | -0.2 | -0.3 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 77.8 | 67.3 | 82.5 | 112 | 123 | 117 | 110 | 115 | 138 | 172 | 174 |
| Sales YoY Gr. | - | -13.5% | 22.6% | 35.2% | 10% | -4.3% | -6.1% | 4.8% | 19.4% | 25% | - |
| Adj EPS ⓘ | -0 | 0.1 | 4.8 | 7.7 | 8.8 | 9.2 | 10 | 11.4 | 11 | 9.7 | 8.2 |
| YoY Gr. | - | NA | 4650% | 62.5% | 14.1% | 4.8% | 7.8% | 14.3% | -2.9% | -12.5% | - |
| BVPS (₹) ⓘ | 17.8 | 17.9 | 24.7 | 63.7 | 73.7 | 98.6 | 104.5 | 114.8 | 146.8 | 159.3 | 168.2 |
| Adj Net Profit ⓘ | 0 | 0.1 | 5 | 9 | 10.3 | 11.3 | 12.2 | 13.9 | 14 | 12.3 | 10 |
| Cash Flow from Ops. ⓘ | -3.3 | 6.2 | 3.6 | -5.5 | 4.3 | 11.7 | 13 | 4.8 | -3.5 | -0.3 | - |
| Debt/CF from Ops. ⓘ | -6.3 | 3.3 | 4.9 | -2.7 | 2.7 | 1 | 1.5 | 5.4 | -7.4 | -121.1 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 9.2% | 7.1% | 16.1% | 25% | ||||
| Adj EPS ⓘ | NA | 1.9% | -1% | -12.5% | ||||
| BVPSⓘ | 27.6% | 16.7% | 15.1% | 8.6% | ||||
| Share Price | 43.6% | 8.4% | -15.5% | -6.3% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -0.2 | 0.6 | 22.4 | 17.8 | 12.8 | 10.8 | 9.5 | 9.8 | 8.2 | 6.1 | 5 |
| Op. Profit Mgn % ⓘ | 6.5 | 8.2 | 14.1 | 15.1 | 14.3 | 15.5 | 18.2 | 20.9 | 17.9 | 15.8 | 13.7 |
| Net Profit Mgn % ⓘ | -0.1 | 0.2 | 6.1 | 8.1 | 8.4 | 9.6 | 11 | 12 | 10.1 | 7.1 | 6 |
| Debt to Equity ⓘ | 1.2 | 1.1 | 0.7 | 0.2 | 0.1 | 0.1 | 0.2 | 0.2 | 0.1 | 0.2 | 0 |
| Working Cap Days ⓘ | 201 | 230 | 197 | 196 | 235 | 287 | 310 | 332 | 358 | 342 | 154 |
| Cash Conv. Cycle ⓘ | 42 | 42 | 37 | 64 | 74 | 71 | 66 | 88 | 128 | 118 | 79 |
Sales growth is growing at healthy rate in last 3 years 16.10%
Sales growth is good in last 4 quarters at 13.38%
Return on Equity has declined versus last 3 years average to 5.00%
Net Profit has been subdued in last 3 years -0.98%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 8.2 | 5.5 |
| TTM Sales (₹ Cr.) | 174 | 182 |
| BVPS (₹.) ⓘ | 168.2 | 164.5 |
| Reserves (₹ Cr.) ⓘ | 201 | 203 |
| P/BV ⓘ | 3.11 | 3.18 |
| PE ⓘ | 63.91 | 95.39 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 356.75 / 630.00 |
| All Time Low / High (₹) | 2.25 / 1219.00 |
| Market Cap (₹ Cr.) | 664 |
| Equity (₹ Cr.) | 12.7 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 44.3 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 78 | 67 | 82 | 112 | 123 | 117 | 110 | 115 | 138 | 172 |
| Operating Expenses ⓘ | 73 | 62 | 71 | 95 | 105 | 99 | 90 | 91 | 113 | 145 |
| Manufacturing Costs | 21 | 20 | 19 | 30 | 22 | 25 | 29 | 24 | 33 | 36 |
| Material Costs | 37 | 29 | 37 | 49 | 69 | 60 | 47 | 44 | 53 | 72 |
| Employee Cost | 5 | 5 | 7 | 9 | 8 | 9 | 9 | 15 | 19 | 22 |
| Other Costs ⓘ | 9 | 8 | 8 | 7 | 6 | 5 | 5 | 9 | 9 | 15 |
| Operating Profit ⓘ | 5 | 6 | 12 | 17 | 17 | 18 | 20 | 24 | 25 | 27 |
| Operating Profit Margin (%) | 6.5% | 8.2% | 14.0% | 15.1% | 14.2% | 15.4% | 18.2% | 20.9% | 17.9% | 15.8% |
| Other Income ⓘ | 1 | 1 | 0 | 2 | 4 | 2 | 1 | 2 | 2 | 2 |
| Interest ⓘ | 4 | 4 | 4 | 3 | 1 | 1 | 2 | 2 | 3 | 6 |
| Depreciation ⓘ | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 6 | 6 | 7 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 0 | 1 | 6 | 14 | 18 | 17 | 17 | 18 | 17 | 17 |
| Tax ⓘ | 0 | 0 | 1 | 4 | 5 | 4 | 4 | 3 | 2 | 4 |
| Profit After Tax | 0 | 0 | 5 | 10 | 12 | 12 | 12 | 15 | 15 | 13 |
| PAT Margin (%) | 0.6% | 0.7% | 6.3% | 9.1% | 9.8% | 10.4% | 11.3% | 12.9% | 10.9% | 7.7% |
| Adjusted EPS (₹) | 0.5 | 0.5 | 4.9 | 8.6 | 10.3 | 10.0 | 10.2 | 12.2 | 11.9 | 10.5 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 12% | 10% | 5% | 10% | 8% | 8% | 10% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 17 | 18 | 26 | 75 | 87 | 122 | 134 | 148 | 193 | 209 |
| Share Capital ⓘ | 10 | 10 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 |
| Reserves ⓘ | 7 | 8 | 15 | 63 | 75 | 110 | 122 | 136 | 180 | 196 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 20 | 18 | 17 | 14 | 12 | 10 | 17 | 24 | 24 | 30 |
| Long Term Debt | 5 | 4 | 2 | 0 | 0 | 2 | 6 | 5 | 1 | 1 |
| Short Term Debt | 16 | 15 | 14 | 14 | 12 | 8 | 11 | 19 | 23 | 29 |
| Trade Payables | 27 | 19 | 22 | 22 | 31 | 32 | 30 | 42 | 46 | 38 |
| Others Liabilities ⓘ | 5 | 5 | 9 | 7 | 8 | 12 | 11 | 11 | 13 | 15 |
| Total Liabilities ⓘ | 69 | 60 | 73 | 118 | 137 | 176 | 192 | 225 | 275 | 292 |
Fixed Assets | ||||||||||
| Gross Block | 35 | 36 | 38 | 46 | 47 | 58 | 116 | 124 | 130 | 136 |
| Accumulated Depreciation | 15 | 17 | 19 | 20 | 22 | 24 | 26 | 32 | 38 | 45 |
| Net Fixed Assetsⓘ | 20 | 19 | 19 | 25 | 24 | 34 | 90 | 92 | 92 | 91 |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 15 | 40 | 0 | 0 | 0 | 0 |
| Investmentsⓘ | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 4 | 8 |
| Inventories | 13 | 11 | 14 | 14 | 15 | 17 | 5 | 27 | 45 | 59 |
| Trade Receivables | 27 | 16 | 26 | 38 | 43 | 44 | 50 | 61 | 60 | 48 |
| Cash Equivalents | 2 | 3 | 3 | 23 | 9 | 2 | 3 | 4 | 20 | 15 |
| Others Assetsⓘ | 7 | 11 | 11 | 17 | 30 | 37 | 43 | 39 | 53 | 71 |
| Total Assets ⓘ | 69 | 60 | 73 | 118 | 137 | 176 | 192 | 225 | 275 | 292 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -3 | 6 | 4 | -5 | 4 | 12 | 13 | 5 | -3 | 0 |
| PBT ⓘ | 0 | 0 | 6 | 14 | 17 | 17 | 17 | 18 | 17 | 17 |
| Adjustment ⓘ | 4 | 5 | 5 | 4 | 2 | 3 | 3 | 7 | 9 | 11 |
| Changes in Working Capital ⓘ | -8 | 1 | -8 | -23 | -11 | -3 | -3 | -17 | -33 | -25 |
| Tax Paid ⓘ | 0 | 0 | 0 | -1 | -4 | -4 | -4 | -3 | 3 | -3 |
| Cash Flow From Investing Activity ⓘ | 0 | -1 | -2 | -8 | -15 | -39 | -18 | -8 | -8 | -9 |
| Capex | 0 | -1 | -2 | -8 | -16 | -38 | -18 | -9 | -6 | -6 |
| Net Investments | 0 | 0 | 0 | 0 | 0 | -2 | 0 | 0 | -2 | -4 |
| Others ⓘ | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Cash Flow From Financing Activityⓘ | 3 | -5 | -1 | 33 | -4 | 21 | 6 | 4 | 28 | 3 |
| Net Proceeds from Shares ⓘ | 1 | 1 | 3 | 39 | 0 | 25 | 0 | 0 | 31 | 3 |
| Net Proceeds from Borrowing ⓘ | 4 | -1 | -1 | -2 | 0 | 2 | 4 | -1 | -4 | 0 |
| Interest Paid ⓘ | -3 | -3 | -3 | -2 | -1 | -1 | -1 | -1 | -3 | -4 |
| Dividend Paid ⓘ | 0 | 0 | 0 | -1 | 0 | -1 | -1 | -1 | -1 | -1 |
| Others ⓘ | 0 | -1 | 0 | 0 | -3 | -4 | 3 | 8 | 5 | 5 |
| Net Cash Flow ⓘ | 0 | 0 | 0 | 20 | -14 | -6 | 1 | 1 | 17 | -6 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 2.66 | 2.76 | 23.5 | 20.12 | 14.96 | 11.86 | 10.06 | 11.12 | 9.2 | 6.85 |
| ROCE (%) | 11.58 | 11.36 | 24.1 | 24.91 | 20.22 | 15.26 | 13.12 | 12.82 | 10.95 | 10.13 |
| Asset Turnover Ratio | 1.17 | 1.05 | 1.24 | 1.17 | 0.96 | 0.75 | 0.6 | 0.55 | 0.55 | 0.61 |
| PAT to CFO Conversion(x) | N/A | N/A | 0.8 | -0.5 | 0.33 | 1 | 1.08 | 0.33 | -0.2 | 0 | Working Capital Days |
| Receivable Days | 110 | 115 | 92 | 105 | 122 | 136 | 155 | 175 | 161 | 115 |
| Inventory Days | 62 | 67 | 55 | 46 | 44 | 50 | 37 | 51 | 95 | 111 |
| Payable Days | 250 | 284 | 200 | 164 | 138 | 191 | 237 | 299 | 302 | 212 |
Medicamen Biotech Limited was incorporated in December 1993, it is a widely held, Globaly Recognized public limited company engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets. Medicamen Biotech Limited is committed to produce and provide quality medicines at competitive price for domestic as well as international markets thereby being socially responsible and rendering services to the medical fraternity since inception.
Medicamen Biotech started its operation as distributor and manufacturer of medicines on loan license basis. The distribution activities were spread manifold over a wide market extending beyond the domestic market and started exporting to CIS countries.The vast distribution network with demand for low cost medicines prompted Mr. B.K. Gupta - Managing Director of the company to go for own manufacturing facilities. Thus in the later part of 1994 a land of 2,10,000 square feet in the Industrial town of Bhiwadi in the state of Rajasthan was procured.
In 1995 Medicamen Biotech Limited was enlisted in Bombay Stock Exchange and public issue was oversubscribed by more than 11 times. Within a span of 10 years Medicamen Biotech Limited is now among top 50 Indian export company.
In the year 2005 keeping the pace with the ever increasing demand and fulfilling the commitment, a second unit was installed in the Tax free zone at Haridwar in the state of Uttarakhand .The Unit II is fully operational from April 2007 with ultra modern manufacturing facilities.
Product range of the company includes:
The company is the Manufacturer and supplier of Comprehensive range of products:
Achievements/ recognition:
The company is the receipents of the following certificates & awards:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
